Autism spectrum disorders (ASDs), which include the prototypic autistic disorder (AD), Asperger's syndrome (AS) and pervasive developmental disorders not otherwise specified (PDD-NOS), are complex neurodevelopmental conditions of unknown aetiology. The current study investigated the metabolites in the methionine cycle, the transsulphuration pathway, folate, vitamin B12 and the C677T polymorphism 
disorder (AD), Asperger syndrome (AS) characterized by no general delay in language or cognitive development and pervasive developmental disorders not otherwise specified (PDD-NOS)
, which is a milder condition that includes some, but not all, of the symptoms associated with classic autism. Once considered a rare clinical entity, autism is now considered common, with the most recent prevalence estimate around 1 in 150 [3, 4] . In the scientific literature, there is varying support for a wide spectrum of hypotheses regarding the causes of autism: from studies showing that genes play a greater role in the risk for autism than in any other common neuropsychiatric disorder [5] to studies implicating disruptive environmental factors during neurodevelopment in genetically susceptible individuals [6] . Nevertheless, it is becoming increasingly obvious that a single cause or unifying theory is unlikely to account for what is now better referred to as 'the autisms' [7, 8] 
. What is both intriguing and frustrating for researchers investigating the pathophysiological basis of this neurodevelopmental group of disorders is that no specific biomarker for autism has been identified yet in order to improve the reliability of behavioural diagnosis.
While inborn errors of metabolism can probably account for less than 5% of autistic individuals [9] , it has recently been suggested that disturbances in one carbon metabolism (Fig. 1) are a frequently encountered feature of autism [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . The metabolic disturbances have been suggested to contribute to the increased oxidative stress and impaired redox homeostasis that have been documented in autism [20] , but also to a diminished capacity for methylation, with consequences on gene expression, neurotransmitter synthesis and, potentially, on neuronal synchronization [16] .
The current study further broadens the metabolic and genetic dataset on the group of ASD patients by assessing one carbon metabolites in plasma, folate and vitamin B12 in serum, and the C677T polymorphism in the MTHFR gene in three groups of children diagnosed with one of the ASD clinical subtypes (i.e. AD, PDD-NOS and AS) as compared to healthy age-and sex-matched controls. Our data suggest that the severity of these impairments vary across the clinical spectrum.

Materials and methods
Participants
The subjects enrolled in this study were 
Plasma metabolites
Total homocysteine, methionine, total cysteine, cystathionine, serine, glycine, ␣-aminobutyrate, N-methylglycine and N, N-dimethylglycine were determined in plasma by stable isotope dilution capillary gas chromatography/mass spectrometry (GS-MS), as previously described by Stabler et al. [21, 22] . 
Serum vitamin B 12 and folate
Statistical analysis
The data are presented as means Ϯ standard error of the mean (S.E.M. 
Fig. 1 Overview of the one carbon metabolism pathway. Abbreviations: S-adenosylhomocysteine (AdoHcy); S-adenosylmethionine (AdoMet); betaine homocysteine methyltransferase (BHMT); cystathionine ␤-synthase (CBS); cystathionine ␥-lyase (CHT); dihydrofolate (DHF); dimethylglycine dehydrogenase (DMGDH); methionine synthase (MS), methylenetetrahydrofolate reductase (MTHFR); tetrahydrofolate (THF).
Results
Metabolic analyses
The results from metabolite measurements in plasma and serum are listed in Table 1 
Genotyping results
The MTHFR C677T genotype data, summarized in [6] [7] [8] 26] . During the last two decades, several studies have indicated disruptions in one carbon metabolism (Fig. 1) accompanying different neurological and psychiatric disorders [27, 28] [10-13, 18, 19] or in immune cells [17] in ASD patients. In the AD group and to a lesser extent in the PDD-NOS group, we found low levels of plasma methionine despite the fact that all children were on an unrestricted diet. Low methionine has been consistently reported in autism by other groups [10, 11, 13] , and it could be the result of low dietary intake. In addition, in both AD and PDD-NOS, we observed low levels of ␣-aminobutyrate, a metabolite of ␣-ketobutyrate. This is consistent with a low methionine input with consequent low flux through the transsulphuration pathway. Repetitive behaviours and insistence on sameness can have a deleterious impact on the patient's ability to feed effectively and receive adequate nutrition. Children with AD and PDD-NOS have been reported to exhibit atypical feeding behaviour, with a highly restricted range of taste-and/or texture-based food choices [29] . Arnold et al. showed that children with autism on an unrestricted diet are significantly more likely to have deficiencies in essential amino acids, including methionine, which is consistent with poor protein nutrition [30] . Nonetheless, children with ASD from a recent study had high protein content in their diet, although they also had a high rate of reported gastrointestinal symptoms without an apparent medical cause [31] .
Discussion
One of the current obstacles in autism research is the clinical heterogeneity of the disorder, which is worsened by the absence of any reliable biological marker. The prototypical AD is diagnosed on the basis of the triad of behavioural impairments (i.e. social interaction, communication and restrained interests
In the present study, we investigated one carbon metabolism in children with ASD, this being the first study with an emphasis on possible differences in the metabolic profiles between the clinical subtypes (i.e. AD, PDD-NOS and AS). Our results confirmed the presence of disturbances in these metabolic pathways, except for patients with the AS clinical subtype, who exhibited normal levels of metabolites. However, we found differences in the severity of the metabolite profiles across the spectrum of autistic disorders, with AD patients exhibiting disturbances in both the methionine cycle and the transsulphuration pathway concomitant with a slightly more prevalent T allele frequency for the MTHFR C677T polymorphism, while patients with the less severe form of the disease (i.e. PDD-NOS) presenting only with disturbances in the methionine
In children with AD, the trend towards lower serine, glycine and N, N-dimethylglycine that accompanies lower methionine suggests that the remethylation pathway is perturbed. The observation that the thermolabile 677T allele of the MTHFR gene, which is associated with a decrease in enzymatic activity to 50-60% in homozygotes [32] , is slightly more prevalent in the typical autism group, suggests that this polymorphism might contribute to the aforementioned metabolic disturbance. Two other studies indicated that the MTHFR C677T polymorphism is associated to a greater [15] or lesser degree [11] [14] or an intracellular deficiency, since the RFC C80A variant of reduced folate carrier has been showed to be more frequent in autistics [11] . Moreover, preliminary data showed that the 19 bp-deletion polymorphism in dihydrofolate reductase (DHFR) is associated with autism, despite normal folate, vitamin B12 and homocysteine levels, and it seems likely that this polymorphism interacts with the MTHFR and RFC single nucleotide polymorphisms to further modify the risk [18] . In addition, other studies have indicated a high prevalence of iron deficiency in AD and AS and that this is associated with falsely increased to normal folic acid levels [33] . In our study we did not evaluate the levels of S-adenosylmethionine (AdoMet) and S-adenosylhomocysteine (AdoHcy), but the available data in the literature consistently suggest an impaired transmethylation capacity in autistic patients (i.e. low AdoMet/AdoHcy ratio) [10, 11] .
Interestingly, we did not observe higher levels of plasma homocysteine in children with AD, in contrast to our previous study in which hyperhomocysteinemia was present in children with ASD, but this was accompanied by suboptimal levels of vitamin B12 [12] . Suh [17] . While in several studies children with ASD exhibited higher levels of vitamin B6 than the control subjects [35] [36] [37] , the activity of pyridoxal kinase and the levels of pyridoxal 5Ј-phosphate had been measured and found to be generally much lower than levels in control subjects [37] . It has also been suggested that the reduced flux through transsulphuration in autism, with a consequent diminished glutathione pool, could also be due to the high levels of androgens described in these patients [13, 38] since testosterone modulates the activity of CBS [39, 40] . The low levels of cysteine and glutathione, the decrease in the ratio of reduced to oxidized glutathione in plasma and the decreased ability to form sulphated metabolites in autistic patients [41] suggest that antioxidant defences are compromised in these patients [20] . Glutathione is also very important to heavy metal detoxification [42] , and the variations in glutathione abnormalities across the ASD suggests the possibility that it might be functionally significant since it was shown that mercury-associated urinary porphyrin levels increase with increasing severity of ASDs [43] [44] [45] [46, 47] ). The methylation deficit resulting from an altered methionine cycle supports the previously suggested contribution of epigenetic mechanisms to the pathogenesis of autism [26] . Aside from this 'metabolic reprogramming' of gene expression, dysfunctionalities in the synthesis of neurotransmitters and phospholipids would also result [28, 48] [16, 50] . On the other hand, the low levels of glutathione, resulting from the decreased flow through transsulphuration in AD, is indicative of an imbalance in the redox homeostasis, and links oxidative stress with membrane lipid abnormalities, inflammation and aberrant immune response that have been observed in autism [20] .
